ライフサイエンスコーパス: cryptococcosis

1 rbated disease in murine models of pulmonary cryptococcosis.

2 Caenorhabditis elegans and rabbit models of cryptococcosis.

3 been reported in the rat model of pulmonary cryptococcosis.

4 hese cells might contribute to resistance to cryptococcosis.

5 required for virulence in a murine model of cryptococcosis.

6 ht be at greater risk for the development of cryptococcosis.

7 s that IgM might contribute to resistance to cryptococcosis.

8 on virulence in a murine inhalation model of cryptococcosis.

9 nuation of virulence in two murine models of cryptococcosis.

10 s analyzed using a mouse inhalation model of cryptococcosis.

11 impact on pathogenicity in animal models of cryptococcosis.

12 pared by using in vivo and ex vivo models of cryptococcosis.

13 for risk stratification of individuals with cryptococcosis.

14 he SREBP pathway as a therapeutic target for cryptococcosis.

15 ts virulence was reduced in a mouse model of cryptococcosis.

16 nate and adaptive pulmonary defenses against cryptococcosis.

17 n 2 (IL-2) in a murine model of disseminated cryptococcosis.

18 oteins in the development and progression of cryptococcosis.

19 responsiveness during experimental pulmonary cryptococcosis.

20 ptible hosts, respectively, for experimental cryptococcosis.

21 s in immunocompetent patients with pulmonary cryptococcosis.

22 bs2-Hog1 MAPK cascade in the pathogenesis of cryptococcosis.

23 nagement of renal transplant recipients with cryptococcosis.

24 fected tissues of patients with disseminated cryptococcosis.

25 y infected mice and a patient with pulmonary cryptococcosis.

26 s that may contribute to the pathogenesis of cryptococcosis.

27 may have in resistance and susceptibility to cryptococcosis.

28 were tested in murine models of disseminated cryptococcosis.

29 n barrier (BBB) is a key unresolved issue in cryptococcosis.

30 ococcus neoformans is the etiologic agent of cryptococcosis.

31 no effect on virulence in an animal model of cryptococcosis.

32 tenuated for virulence in the mouse model of cryptococcosis.

33 e and were hypervirulent in animal models of cryptococcosis.

34 shown to be protective against experimental cryptococcosis.

35 frequently involved with a fatal outcome of cryptococcosis.

36 ounds, may have utility for the treatment of cryptococcosis.

37 g testing was completed in 227 patients with cryptococcosis.

38 rway towards developing a vaccine to prevent cryptococcosis.

39 importance of urease in the pathogenesis of cryptococcosis.

40 ion status, or the subsequent development of cryptococcosis.

41 search for alternative roles for laccase in cryptococcosis.

42 evelopment of vaccination strategies against cryptococcosis.

43 ent was associated with a decreased risk for cryptococcosis.

44 mice prolonged survival in a mouse model of cryptococcosis.

45 a candidate for phase I trial in humans with cryptococcosis.

46 thout fluconazole for primary prophylaxis of cryptococcosis.

47 have promise as therapeutic reagents against cryptococcosis.

48 routine testing of BALs for CrAg to diagnose cryptococcosis.

49 for the eventual use of MAbs in treatment of cryptococcosis.

50 nisms and is therapeutic in murine models of cryptococcosis.

51 y for the prophylaxis and treatment of human cryptococcosis.

52 r polysaccharides important for virulence in cryptococcosis.

53 occus neoformans alters the course of murine cryptococcosis.

54 l protection against development of cerebral cryptococcosis.

55 ted tissues of individuals with disseminated cryptococcosis.

56 is; 4% had invasive aspergillosis and 3% had cryptococcosis.

57 fected tissues are hallmarks of disseminated cryptococcosis.

58 ated the expression of iNOS in rat pulmonary cryptococcosis.

59 o baseline without recurrence or sequelae of cryptococcosis.

60 therapy versus 27.7% with isolated pulmonary cryptococcosis.

61 nes clinically available to treat or prevent cryptococcosis.

62 ws in the environment and can cause systemic cryptococcosis.

63 rmans to colonize organs in murine models of cryptococcosis.

64 uated virulence in a mouse model of systemic cryptococcosis.

65 crophages and virulence in a murine model of cryptococcosis.

66 n B (AmB), the standard of care for treating cryptococcosis.

67 inhalation and intravenous murine models of cryptococcosis.

68 edispose healthy individuals to disseminated cryptococcosis.

69 anti-GM-CSF AAbs than those with extraneural cryptococcosis.

70 increasingly recognized as being at risk for cryptococcosis.

71 coccus gattii (Cga), the causative agents of cryptococcosis.

72 s but also those with unexplained, localized cryptococcosis.

73 n body fluids is useful for the diagnosis of cryptococcosis.

74 may be important for the treatment of ocular cryptococcosis.

75 of more effective antifungal treatments for cryptococcosis.

76 egral part of clinical care of patients with cryptococcosis.

77 h2 cells using a mouse model of experimental cryptococcosis.

78 d cryptococci are critical in the outcome of cryptococcosis.

79 tion and the defects present in uncontrolled cryptococcosis.

80 ed risk of IRS in transplant recipients with cryptococcosis.

81 were validated in a murine model of systemic cryptococcosis.

82 lso have implications for treatment of human cryptococcosis.

83 ise in clinical fungal infections, including cryptococcosis.

84 sed intracranial pressure (ICP) is common in cryptococcosis.

85 o clinical presentation and outcome in human cryptococcosis.

86 s known regarding capsule phenotype in human cryptococcosis.

87 ells, in contributing to the pathogenesis of cryptococcosis.

88 ts were correlated with laboratory-confirmed cryptococcosis.

89 to optimize the management of posttransplant cryptococcosis.

90 e preventive and/or treatment strategies for cryptococcosis.

91 azole, the widely used drug for treatment of cryptococcosis.

92 nts with abnormal mental status, 95% had CNS cryptococcosis.

93 a multicenter cohort of SOT recipients with cryptococcosis.

94 agnoses, the kappa statistic was highest for cryptococcosis (0.67) and CD4 cell count less than 200 (

95 losis (13.9%), bacterial infections (13.9%), cryptococcosis (11.1%), and cerebral malaria (8.3%) were

96 s 5-FC is indicated for C. gattii neurologic cryptococcosis (6 weeks) and when localized to lung (2 w

97 us mycobacteriosis, 79% and 18 (15.51/0.84); cryptococcosis, 76% and 4 (5.80/1.35); and histoplasmosi

98 Among first episode of cryptococcosis, 9% presented with CD4 >=100 cells/muL.

99 Of 475 patients with cryptococcosis, 90% were without HIV (426 of 475) with m

100 In humans, it is responsible for cryptococcosis, a deadly invasive fungal infection that

101 cellular pathogen and the causative agent of cryptococcosis, a disease that is often fatal to those w

102 ococcus neoformans is the causative agent of cryptococcosis, a disease that is uniformly lethal unles

103 Twenty-five of 92 patients had confirmed cryptococcosis; all sera (n = 56) from these patients we

104 However, cryptococcosis also occurs in individuals with apparentl

105 anistic explanation for the enhanced risk of cryptococcosis among individuals with liver diseases, an

106 ormans is an encapsulated fungus that causes cryptococcosis, an opportunistic infection that has rece

107 ry response often seen in AIDS patients with cryptococcosis and candidiasis is not secondary to subop

108 s should maintain awareness of donor-derived cryptococcosis and consider prompt prophylaxis or treatm

109 formans is a fungal pathogen responsible for cryptococcosis and cryptococcal meningitis.

110 ow the same virulence in different models of cryptococcosis and equivalent levels of competition in c

111 ngal pathogen that is the causative agent of cryptococcosis and fatal meningitis in immuno-compromise

112 To determine the incidence of cryptococcosis and its risk factors among human immunode

113 lar glucuronoxylomannan (GXM) is shed during cryptococcosis and taken up by macrophages.

114 n augmenting host resistance to disseminated cryptococcosis and that IFN-gamma is essential for effic

115 n important source of MCP-1 during pulmonary cryptococcosis and that MCP-1 production is actively reg

116 Due to the increasing global risk of cryptococcosis and the emergence of drug-resistant strai

117 es (AM) comprise the initial host defense in cryptococcosis and they may arrest infection before diss

118 ts to distinguish meningeal and nonmeningeal cryptococcosis and to identify clinical characteristics

119 2 of 2 with invasive fusariosis, 1 of 1 with cryptococcosis, and 1 of 2 with zygomycosis.

120 nicilliosis marneffei, 2.9% of patients with cryptococcosis, and 1.1% of patients with aspergillosis.

121 HIV-positive individuals who did not develop cryptococcosis, and in HIV-negative individuals.

122 sent an alternative for the therapy of human cryptococcosis, and monoclonal antibody 18B7 (IgG1) is a

123 tivity, lack of growth in an animal model of cryptococcosis, and morphological defects.

124 mponents that protect mice from disseminated cryptococcosis, and this protection appears to be T-cell

125 ion to their application in the diagnosis of cryptococcosis, anti-GXM mAbs are invaluable tools for s

126 Thus, outcome in transplant recipients with cryptococcosis appears to be influenced by the type of i

127 how that protective immune responses against cryptococcosis are associated with Th1-type cytokine pro

128 approaches for non-meningeal, non-pulmonary cryptococcosis are based on those used for cryptococcal

129 Most cases of cryptococcosis are caused by Cryptococcus neoformans var

130 Because candidiasis and cryptococcosis are common in human immunodeficiency viru

131 nd their possible role in protection against cryptococcosis are not known.

132 r, an increasing proportion of patients with cryptococcosis are now ART experienced.

133 tive approaches to prevention and therapy of cryptococcosis are urgently needed.

134 diagnostic tests (as have been developed for cryptococcosis) are urgently needed for pneumocystosis,

135 ections, including Staphylococcus aureus and cryptococcosis, as well as multidrug-resistant organisms

136 experience clinical deterioration, known as cryptococcosis-associated immune reconstitution inflamma

137 Cryptococcosis-associated immune reconstitution inflamma

138 deterioration, in part caused by paradoxical cryptococcosis-associated immune reconstitution inflamma

139 The armamentarium to decrease cryptococcosis-associated mortality is expanding: crypto

140 gly associated with higher CRP and sST2, and cryptococcosis-associated mortality with higher IL-4 and

141 vered from an immunocompromised patient with cryptococcosis based on molecular analyses available in

142 management of cirrhotic patients who develop cryptococcosis before transplantation are not fully know

143 ving consecutive patients with cirrhosis and cryptococcosis between January 2000 and March 2014.

144 Patients with cryptococcosis between January 2015 and December 2019 we

145 val rates and occurrences of newly diagnosed cryptococcosis between patients with and without flucona

146 reviously healthy patients with disseminated cryptococcosis but also those with unexplained, localize

147 contributed to virulence in a mouse model of cryptococcosis but only in a mutant that also lacked the

148 infection in the murine inhalation model of cryptococcosis but still causes brain infection in a mur

149 activity is involved in the pathogenesis of cryptococcosis but that the importance may be species an

150 stmicin was efficacious in a mouse model for cryptococcosis, but it was less active than predicted fr

151 Among patients with CNS cryptococcosis, C. gattii infection was associated with

152 Ninety percent of cryptococcosis cases occurred in patients without HIV (8

153 Given the increasing prevalence of cryptococcosis caused by Cryptococcus gattii (serotypes

154 We describe the first case of cryptococcosis caused by Cryptococcus neoformans var. ga

155 Ocular cryptococcosis causes blindness and is commonly associat

156 ental for understanding pathogenesis because cryptococcosis commonly presents as meningoencephalitis.

157 We report a case of cryptococcosis due to C. gattii which appears to have be

158 Cryptococcosis due to Cryptococcus neoformans and Crypto

159 ion is often obtained to treat patients with cryptococcosis due to the complex nature of the disease,

160 ion is often obtained to treat patients with cryptococcosis due to the complex nature of the disease,

161 de, for example, management of pretransplant cryptococcosis during transplant candidacy and timing of

162 the absence of CM can represent early-stage cryptococcosis during which antifungal treatment might i

163 Patients with CNS cryptococcosis exhibited a higher serum concentration of

164 ents comprised 83 transplant recipients with cryptococcosis followed for a median of 2.1 and up to 5.

165 The mortality rate of 59% for patients with cryptococcosis following SARS-CoV-2 is higher than that

166 cted a retrospective review of patients with cryptococcosis from 2002 to 2019 at Barnes-Jewish Hospit

167 Our results suggest that FTY720 reactivates cryptococcosis from the granuloma through a S1P receptor

168 Except for cryptococcosis, fungal infection of the central nervous

169 Although cryptococcosis has been associated with birds for almost

170 to the investiagion of fungal pathogenesis, cryptococcosis has been studied extensively at the genet

171 that patients who are at increased risk for cryptococcosis have lower serum levels of GXM-reactive I

172 solid organ transplant (SOT) recipients with cryptococcosis have not been fully defined.

173 i (pneumocystosis), Cryptococcus neoformans (cryptococcosis), Histoplasma capsulatum (histoplasmosis)

174 Africa (GERMS-SA), we reviewed all cases of cryptococcosis in 2005 and 2006.

175 Cryptococcus neoformans from a case of nasal cryptococcosis in a cat.

176 assessed antifungal treatment practices for cryptococcosis in a cohort of prospectively followed org

177 f 122 solid organ transplant recipients with cryptococcosis in a multicenter study from 1999 to 2006.

178 fluence of IgM on susceptibility to systemic cryptococcosis in a murine model, we compared the surviv

179 comprised 54 renal allograft recipients with cryptococcosis in a prospective, multicenter study.

180 ssed in 111 organ transplant recipients with cryptococcosis in a prospective, multicenter, internatio

181 A striking feature of cryptococcosis in AIDS is high serum levels of the major

182 CrAg LFA) was evaluated for the diagnosis of cryptococcosis in HIV-negative patients.

183 causes serious infections in AIDS patients, cryptococcosis in immunologically immature infants, as i

184 stances; potential for donor transmission of cryptococcosis in light of recent fatal transmissions; a

185 chloroquine was therapeutic in experimental cryptococcosis in outbred and severe combined immunodefi

186 Cryptococcosis in patients with cirrhosis has grave prog

187 level of awareness is warranted to diagnose cryptococcosis in patients without HIV.

188 ospective cohort of 147 consecutive cases of cryptococcosis in patients without HIV.

189 ospective cohort of 147 consecutive cases of cryptococcosis in patients without HIV.

190 Limited data exist regarding outcomes of cryptococcosis in patients without human immunodeficienc

191 essive antifungal therapies, outcomes of CNS cryptococcosis in people without HIV are characterized b

192 aspergillosis, zygomycosis, fusariosis, and cryptococcosis in SOT recipients intolerant of or failin

193 ese results indicate that serial episodes of cryptococcosis in South Africa are frequently associated

194 cribe persons with AIDS currently developing cryptococcosis in the era of highly active antiretrovira

195 t a potential role for subclinical pulmonary cryptococcosis in the pathogenesis of asthma.

196 Progression of pulmonary cryptococcosis in the presence of nonprotective T(2) imm

197 the literature, the extent of donor-derived cryptococcosis in the United States has not been documen

198 There is an ongoing outbreak of cryptococcosis in the western United States and Canada.

199 Knowledge of characteristics of cryptococcosis in these patients remains incomplete.

200 apeutic approach and duration of therapy for cryptococcosis in transplant recipients.

201 es related to human papillomavirus (in 29%), cryptococcosis (in 24%), molluscum contagiosum (in 9%),

202 ans causes severe, and often fatal, disease (cryptococcosis) in immunocompromised patients, particula

203 rus (HIV)-positive individuals who developed cryptococcosis, in matched samples from HIV-positive ind

204 In rats with experimental pulmonary cryptococcosis, increased lung levels of TGF were presen

205 host defense in a murine model of pulmonary cryptococcosis induced by intratracheal inoculation of C

206 tream of mice to simulate the antigenemia in cryptococcosis, inhibits PMN accumulation at the site of

207 Cryptococcosis is a disease resulting from the inhalatio

208 Cryptococcosis is a fungal disease caused by Cryptococcu

209 Cryptococcosis is a leading cause of death among individ

210 Cryptococcosis is a leading cause of death among people

211 Cryptococcosis is a significant opportunistic mycoses in

212 Disseminated cryptococcosis is accompanied by cryptococcal polysaccha

213 Cryptococcosis is an invasive infection that accounts fo

214 Cryptococcosis is increasingly recognized in people with

215 Compared to the incidence in adults, cryptococcosis is inexplicably rare among children, even

216 Species identification in patients with cryptococcosis is necessary to discern epidemiologic pat

217 Cryptococcosis is one of the most frequent fungal eye in

218 iciency syndrome (AIDS)-related disseminated cryptococcosis is possible in patients receiving highly

219 Cryptococcosis is very rare, with about 30 cases per yea

220 ce to Cryptococcus neoformans disease (i.e., cryptococcosis) is unknown.

221 ptococcus neoformans, the causative agent of cryptococcosis, is an opportunistic fungal pathogen that

222 ormans, the predominant etiological agent of cryptococcosis, is an opportunistic fungal pathogen that

223 The disease, cryptococcosis, is mostly acquired by inhalation and can

224 In murine models of cryptococcosis, MAb 2H1 administration prolongs survival

225 the rabbit and the mouse models of invasive cryptococcosis, man1 was shown to be severely impaired i

226 eurological damage in HIV- subjects with CNS cryptococcosis may help gauge disease severity and guide

227 resulted in attenuated virulence in a mouse cryptococcosis model that was restored by complementatio

228 d this immunotherapy using a direct cerebral cryptococcosis model to study direct effects in the brai

229 on, abnormal mental status, time to onset of cryptococcosis more than 24 months posttransplantation (

230 spergillosis (n = 20), candidiasis (n = 10), cryptococcosis (n = 9), and histoplasmosis (n = 11) reve

231 constitution syndrome (IRS) in the course of Cryptococcosis neoformans infection in renal transplant

232 Disseminated cryptococcosis occurred in 7 (22%) low-titer and 15 (47%

233 gnificant predictor of future development of cryptococcosis (odds ratio, 14; P = .02).

234 ry B cells in banked samples obtained before cryptococcosis onset from 31 participants in the Multice

235 cal roles in mediating host defenses against cryptococcosis or cryptococcal pathogenesis, the involve

236 report we examine outcomes of patients with cryptococcosis or dimorphic fungal infections treated wi

237 However, an increasing proportion of cryptococcosis patients are now ART-experienced.

238 l fluid (CSF) samples from 44 and 33 non-HIV cryptococcosis patients, respectively.

239 The annual incidence of cryptococcosis per 1000 among persons living with AIDS r

240 Cryptococcosis presented as incidental imaging findings

241 IV-infected persons, the annual incidence of cryptococcosis ranged from 0.2 to 0.9/100,000.

242 rity of the organ transplant recipients with cryptococcosis receive maintenance antifungal therapy fo

243 icantly associated with an increased risk of cryptococcosis; receiving fluconazole within 3 months be

244 Cryptococcosis remains a major cause of mortality in peo

245 Cryptococcosis remains a significant cause of morbidity

246 Still, treating cryptococcosis remains a significant challenge due to th

247 o antifungal agents used in the treatment of cryptococcosis remains uncommon among isolates of C. neo

248 Although resistance to cryptococcosis requires intact T-cell immunity, a possib

249 her studies of the role of B cells in murine cryptococcosis, SCID mice were reconstituted with lympho

250 Participants received tuberculosis and cryptococcosis screening and therapy per World Health Or

251 s have a central role in the pathogenesis of cryptococcosis since they are an important line of defen

252 might confer enhanced resistance to systemic cryptococcosis, stemming in part from the antifungal act

253 gal burden in a murine model of disseminated cryptococcosis, supporting the therapeutic potential of

254 Fifty sera from 67 patients without cryptococcosis tested negative in both assays.

255 selectin in serum samples from subjects with cryptococcosis than in those from uninfected subjects.

256 Gal-3-deficient mice are more susceptible to cryptococcosis than WT animals, as demonstrated by the h

257 ar macrophages, have provided a new model of cryptococcosis that could have broad implications for hu

258 ntent imaging method in a zebrafish model of cryptococcosis that permits the detailed analysis of mac

259 IV-infected individuals who had a history of cryptococcosis (the HIV+CN+ group) with levels in 30 hum

260 had HIV infection and subsequently developed cryptococcosis (the HIV+CN+ group), 8 had HIV infection

261 HIV)-infected subjects who had no history of cryptococcosis (the HIV+CN- group) and 20 HIV-uninfected

262 up), 8 had HIV infection and did not develop cryptococcosis (the HIV+CN- group), and 15 did not have

263 IV-uninfected subjects who had no history of cryptococcosis (the HIV- group) (cohort 1).

264 d not have HIV infection and did not develop cryptococcosis (the HIV- group) (cohort 2).

265 d the intravenous infection models of murine cryptococcosis, the congenic a and alpha strains display

266 In two mouse models of cryptococcosis, the tsa1 Delta mutant is significantly l

267 ) independently identified patients with CNS cryptococcosis; the risk of CNS disease was 14% if none,

268 both BALB/c and C.B-17 mice clear pulmonary cryptococcosis through T cell-mediated mechanisms, Ig H

269 ikelihood of phenotypic switching in chronic cryptococcosis; thus this mechanism may account for the

270 We used the murine intranasal model of cryptococcosis to compare the lethality of clinical and

271 be colonised by cryptococci and can transmit cryptococcosis to humans via inhalation of inoculated bi

272 del, we explored the potential for pulmonary cryptococcosis to modify allergic responses and airway r

273 eal candidiasis, CMV disease, extrapulmonary cryptococcosis, toxoplasmic encephalitis, tuberculosis,

274 Patients with disseminated cryptococcosis typically have measurable levels of crypt

275 Criterion for diagnosis of pulmonary cryptococcosis was (a) the histopathologic presence of t

276 Cryptococcosis was diagnosed a median of 22 days (interq

277 Pulmonary cryptococcosis was diagnosed in 9 (28%) low-titer and 8

278 Central nervous system cryptococcosis was documented in 61 patients.

279 Graft rejection after cryptococcosis was observed in 15.4% (2/13) of the patie

280 The risk of disseminated cryptococcosis was significantly higher for liver transp

281 The course of pulmonary cryptococcosis was studied in more detail in the CD14(-/

282 sitive CrAg LFA results in patients for whom cryptococcosis was ultimately excluded.

283 s age-related difference in the incidence of cryptococcosis, we investigated isolates of C. neoforman

284 passive immunization for treatment of murine cryptococcosis, we noted the occurrence of an acute, let

285 mmunodeficiency virus-infected patients with cryptococcosis were analyzed to determine whether persis

286 SOT recipients with cryptococcosis were identified and followed for 12 month

287 mortem cryptococcal meningitis and pulmonary cryptococcosis were identified at MIA in all 4 CrAg-posi

288 while 17/18 urine samples from patients with cryptococcosis were positive by the LFA.

289 nt patients with clinically proved pulmonary cryptococcosis were retrospectively reviewed by four rev

290 -2019, 58 reports of potential donor-derived cryptococcosis were submitted to DTAC.

291 les from 92 patients with known or suspected cryptococcosis were tested by LA and LFA, and titres wer

292 to reduce AIDS-attributable mortality due to cryptococcosis which remains 20-25% in sub-Saharan Afric

293 mB-tolerant persister formation in pulmonary cryptococcosis, which has potential clinical significanc

294 an encapsulated fungal pathogen that causes cryptococcosis, which is a major opportunistic infection

295 Cryptococcus neoformans are causal agents of cryptococcosis, which manifests as pneumonia and meningi

296 rejection in 66% (2/3) of the patients with cryptococcosis who developed IRS compared to 5.9% (3/51)

297 in 6 patients with a history of disseminated cryptococcosis who had received > or =12 months of antif

298 e strongly considered in SOT recipients with cryptococcosis who have late-onset disease, fungemia, or

299 Of 129 (88%) of 146 SOT recipients with cryptococcosis who underwent CSF analysis, 80 (62%) had

300 ition (n = 11) or began therapy for possible cryptococcosis without improvement (n = 2), leading to a